Literature DB >> 6968602

A technique for the flow cytometric analysis of lymphocytes bearing histamine receptors.

M E Osband, E B Cohen, R P McCaffrey, H M Shapiro.   

Abstract

Histamine receptors have been demonstrated on lymphocyte membranes by a variety of techniques. We now report a method that allows for the flow cytometric analysis of histamine receptors on human peripheral T cells. Histamine is conjugated to fluoresceinated human albumin by the coupling agent ECDI. This conjugated histamine compound (FHA-his) binds to approximately 45% of T cells. Fluoresceinated human albumin alone (FHA), not conjugated to histamine, does not bind to T cells. In addition, unconjugated histamine can inhibit completely the binding seen with FHA-his. We conclude that this technique demonstrates specific FHA-his binding to histamine receptors on T cells and can be used to determine the number of cells bearing such receptors. In addition, the reagent could be used with a cell sorter to isolate distinct histamine-receptor-bearing (HR+) cells for further immunologic study.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968602

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Analysis of 3H-histamine interaction with lymphocytes: receptor binding or uptake?

Authors:  Y Wang; F Kristensen; F Joncourt; D O Slauson; A L De Weck
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

2.  Identification of histamine-receptor leukocytes in the bovine.

Authors:  G A Anderson; J L Stott; B I Osburn
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

3.  Polymorphonuclear leukocyte histamine receptors: occurrence in cell surface clusters and their redistribution during locomotion.

Authors:  H R Petty; J W Francis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  Cimetidine and therapy of rodent tumours.

Authors:  D Hannant; K James; R E Bolton; M D Robertson; I Milne
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.